CCR2 and neoplasm: For example, agents targeting the CCL2/CCR2 axis have shown promise in reducing the recruitment of monocyte-derived TAMs, while inhibitors of colony-stimulating factor 1 receptor (CSF1R) blunt TAM support for tumor growth (35, 36).